Cognision Company Profile

Background

Cognision is a privately held company specializing in neurodiagnostic measurement technologies. Founded in 2003 by Dr. John H. Barker and Kalford C. Fadem, the company is headquartered in Louisville, Kentucky. Cognision's mission is to enhance the assessment and management of cognitive disorders through innovative, user-friendly diagnostic tools. Their flagship product, the COGNISION® System, leverages quantitative electroencephalography (qEEG) and event-related potentials (ERP) to evaluate cognitive functions such as working memory and attention. This technology is instrumental in differentiating between conditions like dementia and depression, tracking disease progression, and assessing overall cognitive deficits.

Key Strategic Focus

Cognision's strategic focus centers on:

Advancing Neurodiagnostic Tools: Developing and refining the COGNISION® System to provide accurate, real-time assessments of cognitive function.

Enhancing Accessibility: Ensuring the system is user-friendly and suitable for various clinical settings, including private practices and large healthcare systems.

Broadening Clinical Applications: Expanding the use of their technology to address a wide range of cognitive disorders, including Alzheimer's disease and concussion/mild traumatic brain injury (mTBI).

Financials and Funding

Cognision has secured approximately $9.1 million in funding through various venture capital investments. Notable investors include:

0924 Investments

Keyhorse Capital (KSTC)

The Vogt Awards

U.S. Department of Health and Human Services

XLerateHealth

These funds have been allocated towards product development, clinical validation, and market expansion initiatives.

Pipeline Development

The primary product in Cognision's pipeline is the COGNISION® System, which has been utilized in over 30,000 tests. The system is FDA-cleared and listed on the Alzheimer's Association website as a medical device that measures synaptic activity related to cognitive function. ERP testing, a component of the system, is recommended by the American College of Occupational and Environmental Medicine for concussion assessments. Cognision continues to invest in research and development to enhance the system's capabilities and expand its clinical applications.

Technological Platform and Innovation

Cognision's innovation is embodied in the COGNISION® System, which features:

Wireless, Battery-Powered Headset: Designed for use in various clinical environments, ensuring flexibility and ease of use.

Subject-Friendly Design: Accommodates a wide range of head sizes, enhancing patient comfort.

Calibrated Insert Earphones: Ensure consistent auditory stimuli during assessments.

Active Electrodes: Provide high signal-to-noise ratio (SNR) and reduce artifacts, improving data quality.

Integrated Action Buttons: Facilitate subject responses during testing.

Hydro-Dot® Biosensors: Easy to apply and deliver low skin contact impedance, enhancing signal quality.

The system utilizes proprietary AI algorithms to quantify brainwave signatures, providing clinicians with real-time, ready-to-read patient reports at the end of each testing session.

Leadership Team

Kalford C. Fadem: Co-Founder and Chief Technology Officer with over 25 years of experience in the medical device industry. He holds a degree in Aerospace Engineering from Georgia Tech.

Marco Cecchi, PhD: Chief Science Officer with a doctorate from the University of Florence. He has conducted postdoctoral research at the University of Texas Health Science Center and the Molecular and Behavioral Neuroscience Institute at the University of Michigan.

Competitor Profile

Market Insights and Dynamics

The neurodiagnostic equipment market is experiencing significant growth, driven by increasing prevalence of cognitive disorders and advancements in diagnostic technologies. The demand for accurate, non-invasive diagnostic tools is on the rise, positioning companies like Cognision favorably within the industry.

Competitor Analysis

Cognision faces competition from several companies offering neurodiagnostic solutions:

NeuroSky: Provides biosensor technologies and systems for health and wellness monitoring.

EMOTIV: Specializes in mobile EEG technology for brain research and consumer applications.

Blackrock Neurotech: Develops implantable brain-computer interfaces for medical applications.

These competitors focus on various aspects of neurotechnology, from consumer applications to medical devices, contributing to a dynamic and competitive market landscape.

Strategic Collaborations and Partnerships

Cognision has engaged in collaborations with universities, major healthcare systems, private practices, hospitals, and global clinical trials to validate and expand the applications of the COGNISION® System. These partnerships have been instrumental in establishing the system's credibility and effectiveness in diverse clinical settings.

Operational Insights

Cognision's strategic considerations include:

Market Positioning: Emphasizing the system's ease of use, accuracy, and versatility to differentiate from competitors.

Regulatory Compliance: Ensuring adherence to FDA regulations and obtaining necessary clearances to facilitate market entry and acceptance.

Reimbursement Strategies: Demonstrating the system's clinical and economic value to secure Medicare reimbursement and adoption by healthcare providers.

Strategic Opportunities and Future Directions

Cognision is poised to capitalize on several strategic opportunities:

Product Enhancement: Continuing to refine the COGNISION® System to improve user experience and diagnostic accuracy.

Market Expansion: Exploring new markets and applications for the system, including additional cognitive disorders and broader geographic regions.

Technological Innovation: Investing in research and development to integrate emerging technologies and maintain a competitive edge in the neurodiagnostic field.